Novel antiseizure medications are thought to be safer than their conventional counterparts, though no dedicated analysis of movement disorder risk among pediatric populations using novel antiseizure medications has been completed. We report a systematic review with meta-analysis describing the relationship between novel antiseizure medications and movement disorders in pediatrics.

MEDLINE, EMBASE, and the World Health Organization’s International Clinical Trials Registry Platform were searched up to October 2020 for randomized controlled trials investigating novel antiseizure medications in pediatric populations. Antiseizure medications included lacosamide, perampanel, eslicarbazepine, rufinamide, fenfluramine, cannabidiol, and brivaracetam. Outcomes were pooled using random effects models; risk difference (RD) and 95% confidence intervals (CIs) were calculated.

Twenty-three studies were selected from 1690 nonredundant manuscripts (n = 1912 total). There was a significantly increased risk of movement disorders associated with perampanel (RD 0.07, 95% CI 0.01-0.13; n = 133), though only 1 relevant trial was found. No increased risk of movement disorders was found with other antiseizure medications.

Our findings indicate most novel antiseizure medications are safe to use in pediatric populations with respect to movement disorders. However, findings were limited by quality of adverse event reporting.

新型抗癫痫药物被认为比传统药物更安全，尽管尚未完成对使用新型抗癫痫药物的儿科人群运动障碍风险的专门分析。我们报告了一项系统综述和荟萃分析，描述了新型抗癫痫药物与儿科运动障碍之间的关系。

MEDLINE、EMBASE 和世界卫生组织的国际临床试验注册平台检索了截至 2020 年 10 月的针对儿科人群新型抗癫痫药物的随机对照试验。抗癫痫药物包括拉科酰胺、吡仑帕奈、艾斯利卡西平、卢非酰胺、芬氟拉明、大麻二酚和布瓦西坦。使用随机效应模型汇总结果；计算风险差 (RD) 和 95% 置信区间 (CI)。

从 1690 份非冗余手稿中选出了 23 项研究（总数 = 1912 份）。尽管仅发现 1 项相关试验，但与吡仑帕奈相关的运动障碍风险显着增加（RD 0.07，95% CI 0.01-0.13；n = 133）。未发现其他抗癫痫药物会增加运动障碍的风险。

我们的研究结果表明，大多数新型抗癫痫药物在治疗运动障碍的儿科人群中使用是安全的。然而，研究结果受到不良事件报告质量的限制。